MyFinsight
Home
Blog
About
Proceeds from at the
market offering
$1,989K
Proceeds from exercise of
pre-funded warrants
$5K
(66.67%↑ Y/Y)
Net cash provided by
financing activities
$1,829K
(-76.06%↓ Y/Y)
Canceled cashflow
$165K
Net decrease in cash
and restricted cash
-$2,560K
(42.21%↑ Y/Y)
Canceled cashflow
$1,829K
Depreciation and
amortization expense
$438K
(-45.32%↓ Y/Y)
Stock-based compensation
$157K
(-86.09%↓ Y/Y)
Accounts payable
$74K
(110.10%↑ Y/Y)
Accounts receivable
-$15K
Change in fair value of
other liabilities and...
$1K
(106.25%↑ Y/Y)
Payment of financing
costs
$118K
(-69.03%↓ Y/Y)
Repayment of financing
lease obligations
$47K
(38.24%↑ Y/Y)
Net cash used in
operating activities
-$4,353K
(63.76%↑ Y/Y)
Canceled cashflow
$685K
Net cash used in
investing activities
-$33K
(48.44%↑ Y/Y)
Effect of exchange rate
changes on cash
-$3K
(-150.00%↓ Y/Y)
Net loss
-$4,160K
(61.56%↑ Y/Y)
Operating lease right of
use liability
-$342K
(55.24%↑ Y/Y)
Accrued expenses and
other current...
-$275K
(81.02%↑ Y/Y)
Prepaid expenses and
other current assets
$261K
(67.31%↑ Y/Y)
Purchases of machinery and
equipment
$33K
(-48.44%↓ Y/Y)
Back
Back
Cash Flow
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)
source: myfinsight.com